Octapharma Overview
Pro stress-test →Octapharma is a family-owned pharmaceutical company based in Switzerland that bills itself as one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As of December 31, 2024, the company employs around 11,000 people worldwide, treating patients in 120 countries.
Strategic Profile
Pro stress-test →The company operates across three therapeutic areas: Haematology (coagulation factor concentrates for bleeding disorders), Immunotherapy (immunoglobulin replacement for immune-mediated diseases), and Critical Care (plasma and protein products for intensive care settings). Octapharma is the largest privately owned and independent plasma fractionator in the world.
Competitive Landscape
Pro stress-test →Octapharma competes in the global plasma therapeutics and recombinant protein markets against large multinational pharmaceutical companies and specialized plasma fractionators. Key competitors in the immunoglobulin and coagulation factor segments include Grifols, CSL Limited, Takeda, and Bioverativ. The immunoglobulins market is projected to grow at 6.2% CAGR through 2027, while bioengineered protein drugs are expected to grow at 8.0% CAGR through 2027.
Industry Context
Octapharma operates in Biopharmaceutical/Plasma Therapeutics.
Key facts
Founded: 1983 · Headquarters: Lachen, Switzerland · Employees: 11,000